Alvotech wins FDA approval for Simlandi production method that doubles batch output

• Alvotech received FDA approval today for a new manufacturing process that doubles active ingredient output per batch for Simlandi, its Humira biosimilar.
• The process requires more than 50% fewer batches for the same Simlandi volume, freeing capacity for other biosimilars.
• FDA clearance earlier this month for a new manufacturing unit in Reykjavík also significantly increases production capacity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200430OMX_____CNEWS_IS_GNW1001278774_is) on October 20, 2026, and is solely responsible for the information contained therein.